Physician profile
Thomas J Wool
NPI 1114924321
$8,319.08
in general payments reported to CMS, 2019-2025
31 companies · $1,583 in 2025
The $1,583 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,222 · 2020: $587 · 2021: $917 · 2022: $998 · 2023: $561 · 2024: $1,451 · 2025: $1,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,153 · Food and Beverage: $1,442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,153.09 |
| Food and Beverage | $1,442.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,809.00 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, S-Icd System Magnet, Resonate El Icd Vr |
| Medtronic, INC. | $1,455.31 | 2021-2025 | Micra |
| Novartis Pharmaceuticals Corporation | $602.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $542.70 | 2019-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $475.58 | 2019-2023 | Opsumit |
| Janssen Pharmaceuticals, INC | $418.32 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $327.71 | 2019-2024 | Lifevest |
| Pfizer INC. | $266.04 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $220.15 | 2019-2024 | Wainua |
| Abbott Laboratories | $209.95 | 2021-2023 | Na |
| Medtronic Vascular, INC. | $170.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $96.85 | 2022-2024 | Verquvo |
| Amgen INC. | $82.54 | 2019-2024 | Repatha |
| Elutia, INC. | $66.80 | 2021-2022 | |
| Philips North America LLC | $63.21 | 2019-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Dd1) Duo Hybrid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $60.65 | 2023 | Inpefa |
| Biotronik INC. | $57.60 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $55.14 | 2019 | |
| Amarin Pharma, INC. | $54.36 | 2019-2020 | |
| Irhythm Technologies, INC. | $46.12 | 2023 | Zio Xt Patch |
| Esperion Therapeutics, INC. | $30.62 | 2020-2021 | |
| Zoll Circulation INC | $22.88 | 2023 | Downstream Cartridge, Therox Ds2 Console, Catheter |
| Novo Nordisk INC | $20.02 | 2024 | Ozempic, Rybelsus |
| United Therapeutics Corporation | $19.94 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $18.81 | 2024 | Arcalyst |
| Cvrx, INC. | $16.91 | 2022 | |
| Gilead Sciences, INC. | $15.53 | 2019 | |
| Atricure, INC. | $13.67 | 2025 | Atriclip Laa Exclusion System |
| Portola Pharmaceuticals, LLC | $12.71 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.